Active Biotech AB
251 articles about Active Biotech AB
Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage
Active Biotech and its partner NeoTX announce the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox, in combination with docetaxel in patients with advanced or metastatic non-small cell lung cancer who have been previously treated with chemotherapy and checkpoint inhibitors.
FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis
Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis.
Annual Report 2021 Active Biotech AB (publ)
Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com.
Active Biotech strengthens the patent protection for laquinimod in eye disorders
Active Biotech announced that the European Patent Office has issued a decision to grant Active Biotech’s patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization.
Active Biotech Interim Report Q1 2022
Active Biotech entered into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis (Feb 9)
Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis
Active Biotech announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in treatment of myelofibrosis.
Active Biotech announces first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma
Active Biotech announced that the first patient has been dosed in the combination part of the phase Ib/IIa clinical study of tasquinimod in relapsed or refractory multiple myeloma.
Active Biotech Appoints Erik Vahtola as Chief Medical Officer
Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer (CMO), effective January 1, 2022.
First subject dosed in phase I clinical study with eye-drop formulation of laquinimod
Active Biotech announced that the first subject has been dosed in the phase I clinical study of the newly developed eye-drop formulation of the company’s candidate drug laquinimod.
Active Biotech's nomination committee appointed
In accordance with a decision made by the Annual General Meeting held on May 19, 2021, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2021, and the Chairman of the Board.
New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that two abstracts with new preclinical data on tasquinimod, a small molecule immunomodulator, have been accepted for presentation at the 63rd ASH Annual Meeting & Exposition in Atlanta, Georgia, December 11-14, 2021.
Active Biotech Interim report January - September 2021
We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer
Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)
Active Biotech and its partner NeoTX announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox, in combination with docetaxel in patients with advanced non-small cell lung cancer.
Active Biotech: Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US
Active Biotech announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone.
Active Biotech AB Interim report January – June 2021
Active Biotech and NeoTX announce FDA clearance of IND for phase II clinical trial of naptumomab
Active Biotech’s partner NeoTX will host KOL webinar on overcoming check point Inhibitor resistance
Active Biotech provided information that its partner in the naptumomab project, NeoTX will host a key opinion leader webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14th at 10 am eastern time
Biogen successfully fended off a patent challenge from generic company Mylan over its multiple sclerosis (MS) drug Tecfidera.
Active Biotech, headquartered in Lund, Sweden, regained the global development and commercialization rights to laquinimod from Israel-based Teva Pharmaceutical Industries.
Active Biotech, based in Lund, Sweden, announced that its laquinimod failed to meet its primary endpoint in its Phase II clinical trial for Huntington’s disease.
The Board has also decided to sell the company's property in Lund as a possible way of generating additional liquidity for the company.